Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845108 | 0.86 | — | — | |
| SCHEMBL17225408 | 0.77 | NOS3 (0.44) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL631537 | 0.74 | MAOA (0.42) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL15763737 | 0.73 | NOS3 (0.52) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL10159213 | 0.71 | NOS3 (0.39) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL13266268 | 0.70 | PDE4D (0.39) | NOS3NOS2ADRA2AADRA2BDRD2 | |
| SCHEMBL12483381 | 0.70 | NOS3 (0.41) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL828997 | 0.69 | — | — | |
| SCHEMBL12160894 | 0.67 | NOS3 (0.47) | NOS3NOS2TAAR1PNMTADRA2A | |
| SCHEMBL6331465 | 0.67 | USP2 (0.47) | NOS2PNMTADRA2AADRA2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | NOS3 153/4885NOS2 155/4885TAAR1 4218/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | NOS3 1913/4885NOS2 1659/4885TAAR1 3278/4885 |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IL15 | NOS3 141/4885NOS2 54/4885TAAR1 3865/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | NOS3 283/4885NOS2 242/4885TAAR1 3684/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | NOS3 1913/4885NOS2 1659/4885TAAR1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.